An experimental evaluation of the effects of banning the sale of flavored tobacco products on adolescents' and young adults' future nicotine vaping intentions.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Some U.S. states and municipalities have banned the sale of flavored tobacco products to help curb youth vaping.

However, evidence supporting such bans is limited.

Who Took Part

The age groups tagged for this paper are teenagers and young adults.

The study was implemented in the RAND StoreLab, a life-sized model convenience store.

The display of flavored tobacco products in the store was manipulated with these conditions: 1) tobacco, sweet, and menthol/mint flavors displayed; 2) only tobacco and menthol/mint displayed; and 3) only tobacco flavors displayed.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Participants were randomly assigned to shop in one of these conditions and completed measures of future vaping intentions post-shopping.

Separate logistic regression models assessed effect of condition on future intentions to use different flavors (tobacco-, menthol/mint-, and sweet-flavored) and any flavor (composite score across flavor categories) of vaping products.

What Was Measured

This experiment tested whether removing flavored tobacco products from a retail setting diminished adolescents' (ages 11-20) future intentions to use vaping products.

The subject headings attached to it are Vaping, Intention, Menthol, Flavoring Agents, Electronic Nicotine Delivery Systems, Tobacco Products and Marketing.

The authors tagged it with the keywords Adolescent, E-cigarettes, Tobacco flavor ban, Tobacco policy and Young adult.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Addictive behaviors), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.